GlassScriptPhysician profile
James A Gunn
NPI 1255643680
$17,444.39
in general payments reported to CMS, 2019-2025
71 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $1,740 · 2021: $3,792 · 2022: $2,611 · 2023: $2,948 · 2024: $2,343 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,714.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,503.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,766.03 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,764.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,395.24 | 2020-2021 | |
| Pfizer INC. | $1,118.68 | 2019-2025 | |
| Lilly USA, LLC | $1,058.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,026.47 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Antares Pharma, INC. | $613.99 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $612.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $448.84 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $429.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.17 | 2019-2025 | Jardiance |
| Abbott Laboratories | $260.69 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $251.47 | 2019-2025 | |
| Allergan, INC. | $239.89 | 2019-2020 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.